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Abstract Synbiotics are known to exert multiple beneficial
effects, including anti-inflammatory and antioxidant actions.
The aim of this study was to evaluate the effects of synbiotic
supplementation on carotid intima-media thickness (CIMT),
biomarkers of inflammation, and oxidative stress in people
with overweight, diabetes, and coronary heart disease
(CHD). This randomized, double-blind, placebo-controlled
trial was conducted and involved 60 people with overweight,
diabetes, and CHD, aged 50–85 years old. Participants were
randomly allocated into two groups to take either synbiotic
supplements containing three probiotic bacteria spices
Lactobacillus acidophilus strain T16 (IBRC-M10785),
Lactobacillus casei strain T2 (IBRC-M10783), and
Bifidobacterium bifidum strain T1 (IBRC-M10771)
(2 × 109 CFU/g each) plus 800 mg inulin or placebo (n = 30
each group) for 12 weeks. Fasting blood samples were taken
at baseline and after the 12-week intervention period to
determine metabolic variables. After the 12-week interven-
tion, compared with the placebo, synbiotic supplementation
significantly reduced serum high-sensitivity C-reactive pro-
tein (hs-CRP) (− 3101.7 ± 5109.1 vs. − 6.2 ± 3163.6 ng/mL,
P = 0.02), plasma malondialdehyde (MDA) (− 0.6 ± 1.0 vs.
− 0.1 ± 0.3 μmol/L, P = 0.01), and significantly increased
nitric oxide (NO) levels (+ 7.8 ± 10.3 vs. − 3.6 ± 6.9 μmol/
L, P < 0.001). We did not observe any significant changes of
synbiotic supplementation on other biomarkers of oxidative
stress and CIMT levels. Overall, synbiotic supplementation
for 12 weeks among people with overweight, diabetes, and
CHD had beneficial effects on serum hs-CRP, plasmaNO, and
MDA levels; however, it did not have any effect on other
biomarkers of oxidative stress and CIMT levels.
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Introduction
Type 2 diabetes mellitus (T2DM) is a metabolic disorder with
common co-morbidities, such as obesity and cardiovascular
disease (CVD) [1]. CVD has been reported to account for 75%
of deaths in diabetic subjects [2]. Multiple pre-existing risk
factors, including CVD, diabetes, and overweight/obesity, in-
crease vulnerability to coronary heart disease (CHD), the lead-
ing cause of death in developed countries [3]. Earlier, the
relationship between carotid intima-media thickness (CIMT)
and metabolic syndrome (MetS) has been assessed in few
studies [4, 5]. In addition, few studies have documented that
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there is a positive association between CIMT and systemic
inflammation [6, 7].
The beneficial effects of synbiotics supplementation on
metabolic profiles have previously reported in patients with
T2DM [8], gestational diabetes mellitus (GDM) [9], non-
alcoholic fatty liver disease [10], and non-obese T2DM [11].
Our previous study showed that taking synbiotic bread con-
taining Lactobacillus sporogenes (108 CFU) plus 0.07 g of
inulin/g for 8 weeks among patients with T2DM significantly
increased plasma nitric oxide (NO) and malondialdehyde
(MDA), but did not affect total antioxidant capacity (TAC)
and total glutathione (GSH) levels [12]. Furthermore,
Kooshki et al. [8] demonstrated that synbiotic supplementa-
tion for 8 weeks among T2DM patients could decrease circu-
lating levels of inflammatory cytokines. In a meta-analysis
study by Tabrizi et al. [13], it was also observed that synbiotic
supplementation among patients with diabetes had beneficial
effects on glycemic control, triglycerides, total- and VLDL-
cholesterol levels. In addition, probiotic intake was benefit in
control of streptozotocin-induced diabetes and its complica-
tions [14]. However, another study indicated that probiotic
supplementation for 6 weeks among patients with T2DM
did not affect high-sensitivity C-reactive protein (hs-CRP)
levels [15].
Synbiotic intake might affect CIMT through amending
markers of inflammation and oxidative stress. Synbiotics
and probiotics might influence biomarkers of inflammation
and oxidative stress through the effect on caveolin-1, endothe-
lial nitric oxide synthase (NOS), neuronal NOS downregula-
tion [16], synthesis of GSH, initiation of apoptosis, and the
upregulation of oxidative pentose pathway activity [17]. To
our knowledge, data on the effects of synbiotic supplementa-
tion on CIMT and biomarkers of inflammation and oxidative
stress in people with overweight, diabetes, and CHD are
scarce. Therefore, the purpose of this study was to evaluate
the effects of synbiotic supplementation on CIMT and bio-
markers of inflammation and oxidative stress in these patients.
Materials and Methods
Participants and Ethics Statements
The current study was a randomized, double-blind,
placebo-controlled trial, registered in the Iranian registry
o f c l i n i c a l t r i a l s ( h t t p : / / w w w . i r c t . i r :
IRCT201503025623N37), conducted at a cardiology
clinic affiliated to Kashan University of Medical Sciences
(KUMS), Kashan, Iran, between March 2015 and
March 2016. This study was done according to the
principals of the Declaration of Helsinki, and the study
protocol was approved by the ethics committee of KUMS.
All patients were informed about the aims and protocol of
the study. Written informed consent was obtained from all
subjects prior to the intervention. Overweight (BMI = 25–
29.9 kg/m2) and obese individuals (obese BMI ≥ 30 kg/m2)
with T2DM, aged 40–85 years old with CHD, were
included. Diagnosis of T2DM was conducted based on
the criteria of the American Diabetes Association [18],
and diagnosis of CHD was performed based on the
American Heart Association [19]. Those consuming
synbiotics and/or probiotics supplements within the past
3 months, changes in the dosage and kind of medications,
taking anti-inflammatory drugs like corticosteroids, having
a myocardial infarction within the past 3 months, having
cardiac surgery within the past 3 months, and significant
renal of hepatic failure were not included in this study.
Study Design
At the onset of the study, all participants were categorized
according to age (< 60 and ≥ 60 years), BMI (25–29.9 and
≥ 30 kg/m2), gender (19 females and 11 males in each
group), and the dosage and kind of medications. Then, par-
ticipants in each block were randomly allocated into two
treatment groups to take either synbiotic supplements con-
taining three probiotic bacteria spices Lactobacillus
acidophilus strain T16 (IBRC-M10785), Lactobacillus
casei strain T2 (IBRC-M10783), and Bifidobacterium
bifidum strain T1 (IBRC-M10771) (2 × 109 CFU/g each)
plus 800 mg inulin or placebo (n = 30 each group) daily for
12 weeks. Synbiotic and placebo capsules were made by
Tak Gen Zist Pharmaceutical Company (Tehran, Iran).
Placebos (starch) were similar in color, shape, size, and
package to the synbiotic capsules. It is well known that it
would be more appropriate if the strains used in probiotic
supplements for human consumption derived from the hu-
man intestinal tract are well characterized, able to outlive
the rigors of the digestive tract and possibly colonize, bio-
logically active against the target, as well as to be stable and
amenable to commercial production and distribution [20].
Due to the lack of evidence about the appropriate dosage of
probiotics for people with overweight, diabetes, and CHD,
we used the abovementioned doses based on few previous
studies in healthy subjects [21, 22]. Compliance to the trial
protocol was evaluated by unused containers of the
synbiotic and placebo capsules which were returned to the
investigators. Moreover, we sent a reminder on subjects’
cell phones regarding consumption of supplements. Three
dietary records and physical activity records as metabolic
equivalents (METs) in hours per day at weeks 0, 3, 6, 9, and
12 of the trial were obtained from each participant. We used
modified Nutritionist IV software (First Databank, San
Bruno, CA) to establish average daily nutrient intakes of
patients.
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Assessment of Anthropometric Measures
Weight and height (Seca, Hamburg, Germany) were measured
without shoes in light clothing in the cardiology clinic by a
trained nutritionist, at baseline and at the end of the study.
BMI was calculated as weight (kg) divided by height squared
(m2).
Clinical Assessment
Measurements of the CIMT (maximum and mean of left and
right CIMT) were carried out in the patients at the 2-cm dis-
tance of the common carotid bifurcation, by the same
sonographist, at baseline and after the 12-week treatment
using a Doppler ultrasonography device (Samsung Medison
V20, Korea) with linear multifrequencies of 7.5- to 10-MHz
probe. The physician was blinded to any clinical information
of the participants. Systolic (SBP) and diastolic blood pressure
(DBP) was quantified via a sphygmomanometer (ALPK2,
Zhejiang, China).
Biochemical Assessment
Ten milliliters fasting blood samples were taken at baseline
and after the 12-week intervention at Kashan Reference
Laboratory, Kashan, Iran. Serum hs-CRP values were
assessed by an ELISA kit (LDN, Nordhorn, Germany) with
inter- and intra-assay coefficient variances (CVs) of 4.6 to
7.0%, respectively. The plasma NO using Griess method
[23], TAC by the method of ferric reducing antioxidant power
developed by Benzie and Strain [24], total GSH using the
method of Beutler et al. [25], and MDA concentrations by
the thiobarbituric acid reactive substances spectrophotometric
test [26] were determined. CVs for plasma TAC, GSH, and
MDAwere lower than 5%.
Randomization
Randomization assignment was conducted using computer-
generated random numbers. Randomization and allocation
concealments were done from the researchers and participants
and were carried out by a trained staff member at the cardiol-
ogy clinic.
Statistical Methods
The Shapiro-Wilk test was applied to control the normal dis-
tribution of variables. The intention-to-treat (ITT) analysis of
the primary study end-point was conducted for all of the ran-
domly allocated subjects. For non-normally distributed vari-
ables (hs-CRP, GSH, MDA, and SBP), we applied Log trans-
formation. Independent sample t test was used to establish
changes in anthropometric measures and dietary intakes
between the two groups. Differences in proportions were eval-
uated by Fisher’s exact test. To compare within-group differ-
ences (before and after treatment), we used paired-samples t
tests. To determine the effects of synbiotic supplementation on
CIMT, biomarkers of inflammation, and oxidative stress, we
used one-way repeated measures ANOVA. Adjustment for
changes in baseline values of biochemical parameters was
performed by analysis of covariance (ANCOVA) using gen-
eral linear models. P < 0.05 was considered statistically sig-
nificant. All statistical analyses were conducted using the
Statistical Package for Social Science version 18 (SPSS Inc.,
Chicago, Illinois, USA).
To calculate sample size, we used the standard formula
suggested for clinical trials by considering type one error (α)
of 0.05 and type two error (β) of 0.20 (power = 80%). Based
on a previous study [8], we used 1.96 mg/L as SD and
1.57 mg/L as the difference in mean (d) of hs-CRP as key
variable. Based on this, we needed 25 persons in each group.
Assuming five dropouts in each group, the final sample size
was determined to be 30 persons per group.
Results
During the intervention phase of the study, two participants
were excluded from the synbiotic group [withdrawn due to
personal reasons (n = 2)] and three [withdrawn due to personal
reasons (n = 3)] from the placebo group (Fig. 1). However, all
60 participants were included in the final analysis using ITT
principle. Overall, the compliance rate was high, such that
higher than 90% of capsules were taken throughout the study
in both groups. No side effects were reported following the
supplementation of synbiotics in people with diabetes and
CHD throughout the study.
There was no statistically significant difference in mean
age, height, weight, BMI, and METs at pre- and post-
intervention between the two groups (Table 1). Mean
smoking, consumption of antidiabetic and antilipidemic
drugs, hypertension rate, consumption of angiotensin-
converting enzymes inhibitors, aldosterone receptor blockers
drugs, and blocker drugs (β-blocker and calcium channel
blocker) of study participants were not statistically different
between the two groups.
Considering the 3-day dietary records obtained during the
intervention, there was no statistically significant difference in
terms of daily dietary macro- and micro-nutrient intakes be-
tween synbiotic and placebo groups (Table 2).
After the 12-week intervention, compared with the placebo,
synbiotic supplementation significantly decreased serum hs-CRP
(− 3101.7 ± 5109.1 vs. − 6.2 ± 3163.6 ng/mL, P = 0.02), plasma
MDA (− 0.6 ± 1.0 vs. − 0.1 ± 0.3 μmol/L, P = 0.01), and
significantly increased NO levels (+ 7.8 ± 10.3 vs.
− 3.6 ± 6.9 μmol/L, P < 0.001) (Table 3). We did not observe
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any significant changes of synbiotic supplementation on other
biomarkers of oxidative stress and CIMT levels.
Baseline levels of plasma NO (P = 0.003), GSH (P = 0.01),
and SBP (P = 0.02) were significantly different between the
two groups. Therefore, we controlled the analyses for the
baseline levels. When we adjusted the analyses for baseline
values of biochemical variables, our findings did not alter
(Table 4).
Discussion
To the best of our knowledge, this study is the first report of
synbiotic supplementation onCIMT, biomarkers of inflamma-
tion, and oxidative stress in people with overweight, diabetes,
and CHD. We found that synbiotic supplementation for
12 weeks among people with overweight, diabetes, and
CHD had beneficial effects on serum hs-CRP, plasma NO,
and MDA levels; however, it did not have any effect on other
biomarkers of oxidative stress and CIMT levels.
Hypertension, inflammation, and oxidative stress increase
the risk of atherosclerosis and CHD in patients with 2DM
[27]. Our data supported that synbiotic supplementation for
12 weeks to people with overweight, diabetes, and CHD sig-
nificantly decreased serum hs-CRP and significantly in-
creased plasma NO concentrations, but did not affect CIMT
levels. Earlier, some studies have assessed the effects of
synbiotic supplementation on inflammatory cytokines.
Supporting our study, synbiotic supplementation for 8 weeks
among T2DM patients could reduce serum hs-CRP concen-
tration [8]. Cheng et al. [28] also demonstrated that soy milk
containing Streptococcus thermophiles and Lactobacillus
plantarum instigated NO production and endothelial NO syn-
thase activity in umbilical vein endothelial cells. In addition,
we have previously indicated that intake of a synbiotic food
containing Lactobacillus sporogenes (27 × 107 CFU) plus
1.1 g inulin for 6 weeks in diabetic patients resulted in a
significant reduction in serum hs-CRP levels [29]. In contrast,
a 3-month intake of synbiotic supplements did not affect in-
flammatory factors in healthy elderly individuals [30]. In ad-
dition, probiotic supplementation for 6 weeks in T2DM pa-
tients did not influence serum hs-CRP concentrations [15].
Diabetes and CVD are associated with increased concentra-
tions of biomarkers of inflammation and oxidative stress [31].
Previous studies have documented that endothelium in indi-
viduals with diabetes might not able to produce sufficient
amount of NO, which in turn blood vessels fail to relax in
response to endothelium-dependent vasorelaxants [32].
Endothelial dysfunction is predictive of future CVD events
[33]. Therefore, decreasing levels of hs-CRP and increasing
levels of NO by synbiotics and/or probiotics may decrease
CVD events. Few mechanisms may explain the beneficial
effects of synbiotic on inflammatory markers. The upregula-
tion of interleukin-18 (IL-18) gene expression by produced
short-chain fatty acids (SCFA) [34] and increased production
of methylketones family in gut following the intake of
synbiotic [35] might result in its anti-inflammatory effects.
In addition, probiotic intake may decrease inflammatory
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factors through modulating the toll-like receptors (TLRs)-mi-
togen-activated protein kinase-peroxisome proliferator-acti-
vated receptor gamma (PPAR-γ) signaling pathways and in-
testinal microbiota [36]. Data have already showed that
PPAR-γ activation may inhibit the activation of TLR4 signal-
ing cascade [37]. Moreover, the activation of PPAR-γ has
been demonstrated to decrease inflammation by suppressing
the activation of nuclear factor-κB (NF-κB) [38]. Another
Table 2 Dietary intakes of study
participants throughout the study Placebo group (n = 30) Synbiotic group (n = 30) P
1
Energy (kcal/day) 2159 ± 230 2171 ± 244 0.85
SFAs (g/day) 23.7 ± 5.2 23.7 ± 5.9 0.97
Omega-3 fatty acids (g/day) 1.2 ± 0.4 1.2 ± 0.5 0.77
Omega-6 fatty acids (g/day) 18.0 ± 8.7 18.3 ± 9.3 0.88
Magnesium (mg/day) 238.2 ± 50.2 259.6 ± 59.8 0.13
Selenium (μg/day) 49.9 ± 13.0 47.8 ± 12.1 0.51
Manganese (mg/day) 1.8 ± 0.8 2.0 ± 0.8 0.34
Vitamin C (mg/day) 138.2 ± 58.9 149.1 ± 39.6 0.40
Vitamin A (μg/day) 571.0 ± 142.3 604.8 ± 124.2 0.33
Vitamin E (mg/day) 10.9 ± 1.9 11.5 ± 2.1 0.27
Data are means ± SDs
1Obtained from independent t test
SFAs, saturated fatty acids
Table 1 General characteristics
of study participants Placebo group (n = 30) Synbiotic group (n = 30) P
1
Age (year) 64.0 ± 11.7 64.2 ± 12.0 0.94
Gender
Female 19 (63.3%) 19 (63.3%) 1†
Male 11 (36.7%) 11 (36.7%)
Duration of diabetes mellitus (year) 6.9 ± 1.8 7.0 ± 1.7 0.88
Height (cm) 158.5 ± 10.8 156.4 ± 6.8 0.39
BMI at study baseline (kg/m2) 29.6 ± 4.6 32.3 ± 6.0 0.05
BMI change (kg/m2) 0.1 ± 0.6 − 0.01 ± 0.5 0.51
MET-h/day at study baseline 26.7 ± 1.9 26.4 ± 1.9 0.53
MET-h/day change − 0.01 ± 1.0 0.05 ± 0.8 0.76
Smoking (%) 3 (10.0) 3 (10.0) 1.00†
Aspirin 80 mg (%) 30 (100) 30 (100) 1.00†
Statin (%) 30 (100) 30 (100) 1.00†
Insulin therapy (%) 9 (30.0) 8 (26.7) 1.00†
Antidiabetic drugs (%)
Monotherapy 16 (66.7) 16 (69.6)
Combination therapy 8 (33.3) 7 (30.4) 1.00†
Hypertension (%) 23 (76.7) 22 (73.3) 1.00†
ACEI/ARB drugs (%) 30 (100) 30 (100) 1.00†
Blocker drugs (%)
β-blocker 27 (90.0) 28 (93.3)
Calcium channel blocker 3 (10.0) 2 (6.7) 1.00†
Data are means ± SDs
1Obtained from independent t test
†Obtained from Fisher’s exact test
ACEI, angiotensin-converting enzymes inhibitors; ARB, aldosterone receptor blockers; METs, metabolic
equivalents
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mechanism for anti-inflammatory effect of probiotics is mod-
ulating signaling pathway of tumor necrosis factor-alpha
(TNF-α) and NF-κB. CRP is synthesized by the liver in re-
sponse to releasing factors by fat cells such as interleukin 6
(IL-6) [39]. In a study by Hegazy et al. [40], it was observed
that the consumption of probiotic in patients with ulcerative
colitis for 8 weeks significantly ameliorated the inflammation
by decreasing concentrations of IL-6, expression of TNF-α,
and NF-κB. Furthermore, decreased superoxide anion, and
hydroperoxides, such as MDA by synbiotics [41], may result
in increased NO levels.
Our study demonstrated that synbiotic supplementation for
12 weeks to people with overweight, diabetes, and CHD re-
sulted in a significant reduction in plasma MDA concentra-
tions, but did not influence TAC and GSH levels. We have
previously shown that probiotic supplementation for 6 weeks
among women with GDM had beneficial effects on plasma
TAC, MDA, and oxidative stress index, but did not affect
plasmaGSH levels [42]. In line with our findings, in an animal
study, the administration of oligofructose, inulin, and the two
Bifidobacterium infantis for 7 days was associated with a sig-
nificant reduction in MDA levels [43]. In addition, a signifi-
cant decrease in MDA levels was observed following the sup-
plementation of probiotic for 30 days in rabbits [44].
Supplementation with synbiotic for 30 days to lactating
mothers had positive effects on MDA concentrations in hu-
man breastmilk [45]. However, some investigators did not
observe the beneficial effects of synbiotic supplementation
on biomarkers of oxidative stress. For example, taking
synbiotic diet containing Lactobacillus plantarum and
Bacillus coagulans plus inulin for 6 weeks in an animal study
did not affect MDA levels [46]. Furthermore, probiotic sup-
plementation for 7 days among critically ill patients [47] and
taking multispecies probiotics supplements (1010 CFU/day)
for 14 weeks among trained men did not influence MDA
levels [48]. The different findings might be explained by dif-
ferent study designs, different dosages of probiotics and inulin
used, the lack of considering baseline levels of dependent
variables, as well as different individuals of the study.
Increased lipid peroxidation especially MDA maybe is asso-
ciated with many diseases, including cancer, CVD, and dia-
betes mellitus [49]. In addition, lipid peroxidation has a key
role in the pathogenesis and the complications of diabetes
[49]. Therefore, synbiotics due to their anti-oxidative actions
may be useful to decrease metabolic complications result from
increased oxidative stress. Synbiotic intake may decrease
MDA levels through reduced inflammatory markers result
from produced SCFA in the gut [50], and its effect in de-
creased oxidized LDL and 8-isoprostanes [51]. In addition,
antioxidant power of tissues can be accomplished by several
mechanisms among which activities of antioxidant enzymes
as superoxide dismutase (SOD) and glutathione peroxidase
(GPx). In a study by Ghoneim et al. [44], probiotic supple-
mentation increased activities of SOD and GPx in all studied
organs although some of which was not significant.
Furthermore, the antioxidant effects of probiotics may be
due to activating nuclear factor erythroid 2-related factor 2
(Nrf2). Nrf2 serves as a master regulator of a cellular defense
system against oxidative stress [52]. In a study by Gao et al.
[53], Lactobacillus plantarum markedly increased the gene
expression of Nrf2.
Our study had a number of limitations. We did not assess the
compliance to synbiotic supplementation by the use of a bio-
marker, and SCFA and fecal bacterial loads. In addition, duration
of the study was brief. Longer duration of the intervention may
have better effects on CIMT. In the current study, we used a
Table 4 Adjusted changes in
carotid intima-media thickness,
biomarkers of inflammation, and
oxidative stress in people with
overweight, diabetes, and coro-
nary heart disease
Placebo group (n = 30) Synbiotic group (n = 30) P1
Mean left CIMT (mm) 0.004 ± 0.01 − 0.002 ± 0.01 0.80
Maximum left CIMT (mm) − 0.006 ± 0.02 − 0.01 ± 0.02 0.86
Mean right CIMT (mm) − 0.01 ± 0.01 − 0.02 ± 0.01 0.63
Maximum right CIMT (mm) − 0.02 ± 0.01 − 0.01 ± 0.01 0.83
hs-CRP (ng/mL) − 433.3 ± 743.2 − 2632.3 ± 743.2 0.04
NO (μmol/L) − 3.4 ± 1.7 7.6 ± 1.7 < 0.001
TAC (mmol/L) 30.0 ± 33.6 49.8 ± 33.6 0.67
GSH (μmol/L) 12.2 ± 17.1 23.6 ± 17.1 0.64
MDA (μmol/L) − 0.1 ± 0.1 − 0.6 ± 0.1 0.004
SBP (mmHg) − 3.1 ± 2.8 − 1.2 ± 2.8 0.63
DBP (mmHg) 0.9 ± 1.5 − 0.9 ± 1.5 0.40
All values are means ± SEs. Values are adjusted for baseline values
1 Obtained from ANCOVA
CIMT, carotid intima-media thickness; CHD, coronary heart disease; DBP, diastolic blood pressure; GSH, total
glutathione; hs-CRP, high-sensitivity C-reactive protein; MDA, malondialdehyde; NO, nitric oxide; TAC, total
antioxidant capacity, T2DM, type 2 diabetes mellitus; SBP, systolic blood pressure
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synbiotic containing mixed bacterial species plus inulin. In addi-
tion, one can conclude if the treatment effects observed in the
current study was due to the effect of which component of the
supplements. Therefore, further studies are needed with single
supplements used in the current study in order to assess beneficial
effects on biomarkers of inflammation and oxidative stress.
Moreover, we did not collect stool samples from participants,
so we did not know whether any of the probiotics survived in
the colon.
Overall, synbiotic supplementation for 12 weeks among
people with overweight, diabetes, and CHD had beneficial
effects on serum hs-CRP, plasma NO, and MDA levels; how-
ever, it did not have any effect on other biomarkers of oxida-
tive stress and CIMT levels. This suggests synbiotic supple-
mentation may confer advantageous therapeutic potential for
people with overweight, diabetes, and CHD management.
Further research is needed in other patients with longer pe-
riods to determine the safety of this supplemental approach.
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